ABOUT / THE PUBLISHER
About PT-141 Compound: what this site is, and what it is not.
An independent editorial digest of the PT-141 (bremelanotide) research record — the one approved use, the off-label male research, and the cited tolerability profile, read straight from the literature.
What PT-141 Compound is
PT-141 Compound is an independent editorial project that publishes summaries of the peer-reviewed research literature and the approved drug label for PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The approach is data-forward: every clinical claim on this site is tied to a specific study or to the FDA prescribing information, and the editorial spine separates what is approved from what is investigational on every page. The single FDA-approved use — HSDD in premenopausal women — is stated before anything else, and the off-label male-erectile research is presented as exactly that: early-phase and not approved.
Why a 'Compound' site, and what the word means here
The domain name carries the word "compound." That is an editorial framing — a position we occupy relative to the chemistry and the literature of a particular molecule — not a claim about services. This site is a research digest of a folded heptapeptide and its evidence base, not a pharmacy, a checkout, or a place to obtain anything.
We organize the record the way the data is shaped: one approved indication, a bounded off-label research story, and a concrete tolerability ledger. Where the evidence is strong, we say so plainly. Where it is contested — the modest effect sizes, the disputed older studies — we leave the disagreement in plain view rather than smoothing it over.
Our editorial standards
Three rules govern everything here. First, cite the source: every quantitative clinical claim maps to a numbered reference — a peer-reviewed study, the FDA label, or an NIH monograph. Second, separate evidence from anecdote: where we summarize community experience, we fence it off explicitly as unverified field reports, attribute nothing anecdotal to a journal, and keep it out of the cited sections. Third, recommend nothing: we report the doses studied in trials and specified on the label as findings, never as a protocol for any individual.
We do not name competitor drug brands, we do not link to other sites we operate, and we do not invent authors or experts. The work stands on the published record and the label, nothing else. For the underlying sources, see the full reference list.